Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 5/20 | 0.39 |
| ▸ | DRD3 | P35462 | 4/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL79036 | 0.92 | ALDH1A1 (0.42) | SRD5A1ALDH1A1CYP3A4ACHEDRD2 | |
| SCHEMBL31236154 | 0.83 | ACHE (0.47) | SRD5A1ALDH1A1CYP3A4ACHEMAPT | |
| SCHEMBL30930042 | 0.83 | ACHE (0.47) | SRD5A1ALDH1A1CYP3A4ACHEMAPT | |
| SCHEMBL27246033 | 0.83 | ACHE (0.47) | SRD5A1ALDH1A1CYP3A4ACHEMAPT | |
| SCHEMBL80428 | 0.83 | ACHE (0.47) | SRD5A1ALDH1A1CYP3A4ACHEMAPT | |
| Hydrochloric Acid SCHEMBL31426377 | 0.81 | ACHE (0.46) | SRD5A1ALDH1A1CYP3A4ACHEMAPT | |
| SCHEMBL13184629 | 0.80 | ALDH1A1 (0.47) | SRD5A1ALDH1A1CYP3A4ACHEMAPT | |
| SCHEMBL23607149 | 0.78 | DRD2 (0.62) | ALDH1A1ACHEDRD2DRD3MAPT | |
| SCHEMBL16233587 | 0.78 | PNMT (0.47) | SRD5A1DRD2DRD3DRD4HTR2A | |
| SCHEMBL11985168 | 0.78 | GRIN2B (0.43) | ALDH1A1DRD2DRD3DRD4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109929328-B | Composite ink and preparation method and device thereof | TCL科技集团股份有限公司 | 2021-10-22 | — | — | CN | claimed |
| US-20200373508-A1 | ELECTROLUMINESCENT MATERIAL INK AND ELECTROLUMINESCENT DEVICE THEREOF | GUANGDONG JUHUA PRINTED DISPLAY TECHNOLOGY CO., LTD. (CN) | 2020-11-26 | — | — | US | claimed |
| CN-108948865-B | Electroluminescent material ink and electroluminescent device thereof | 广东聚华印刷显示技术有限公司 | 2020-07-10 | — | — | CN | claimed |
| CN-109929328-A | A kind of compound ink and preparation method thereof, device | TCL集团股份有限公司 | 2019-06-25 | — | — | CN | claimed |
| CN-108948865-A | Electroluminescent material ink and its electroluminescent device | 广东聚华印刷显示技术有限公司 | 2018-12-07 | — | — | CN | claimed |
| US-11637257-B2 | Electroluminescent material ink and electroluminescent device thereof | GUANGDONG JUHUA PRINTED DISPLAY TECHNOLOGY CO. LTD (CN) | 2023-04-25 | — | — | US | disclosed |
| CN-109929328-B | Composite ink and preparation method and device thereof | TCL科技集团股份有限公司 | 2021-10-22 | — | — | CN | disclosed |
| US-20200373508-A1 | ELECTROLUMINESCENT MATERIAL INK AND ELECTROLUMINESCENT DEVICE THEREOF | GUANGDONG JUHUA PRINTED DISPLAY TECHNOLOGY CO., LTD. (CN) | 2020-11-26 | — | — | US | disclosed |
| CN-108948865-B | Electroluminescent material ink and electroluminescent device thereof | 广东聚华印刷显示技术有限公司 | 2020-07-10 | — | — | CN | disclosed |
| CN-109929328-A | A kind of compound ink and preparation method thereof, device | TCL集团股份有限公司 | 2019-06-25 | — | — | CN | disclosed |
| CN-108948865-A | Electroluminescent material ink and its electroluminescent device | 广东聚华印刷显示技术有限公司 | 2018-12-07 | — | — | CN | disclosed |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20040162408-A1 | PROCESS FOR THE MANUFACTURE OF TEMPERATURE-SENSITIVE POLYMERS | SOLUTIA INC. (US) | 2004-08-19 | — | — | US | disclosed |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | GILEAD PHARMASSET LLC | 2003-09-18 | — | — | US | disclosed |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | PHARMASSET, INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003063771-A2 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | PHARMASSET LTD. (BB) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003051298-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051306-A2 | N4-ACYLCYTOSINE-1,3-DIOXOLANE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
| US-20020165421-A1 | Process for the manufacture of temperature-sensitive polymers | SOLUTIA INC. | 2002-11-07 | — | — | US | disclosed |
| US-3997616-A | FROM ALKENYLBENZENE, CYCLIZATION CATALYST | TEIJIN LIMITED (JA) | 1976-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | ENTPD5, CDA, ADA | SRD5A1 364/4885ALDH1A1 645/4885CYP3A4 740/4885 |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | DERA, DPYD, DHPS | SRD5A1 682/4885ALDH1A1 14/4885CYP3A4 1525/4885 |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, DUT, NT5C3B | SRD5A1 530/4885ALDH1A1 2341/4885CYP3A4 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.